MedTrace Logo

Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy

NCT02332642 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2017-03-07

No results posted yet for this study

Summary

This pilot clinical trial aims at evaluating immuno-modulating effects of palliative treatment with specifically dosed standard chemotherapeutics in patients with metastatic melanoma (AJCC stage IV) by assessing myeloid-derived suppressor cells' (MDSCs) count and activity.

Conditions

  • Immuno-monitoring

Interventions

OTHER

Immuno-monitoring

Sponsors & Collaborators

  • Universitätsmedizin Mannheim

    lead OTHER

Principal Investigators

  • Christoffer Gebhardt, M.D. · Universitätsmedizin Mannheim

  • Jochen Utikal, M.D. · Universitätsmedizin Mannheim

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02332642 on ClinicalTrials.gov